0000899243-22-034069.txt : 20221024 0000899243-22-034069.hdr.sgml : 20221024 20221024185804 ACCESSION NUMBER: 0000899243-22-034069 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221020 FILED AS OF DATE: 20221024 DATE AS OF CHANGE: 20221024 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wheadon David E. CENTRAL INDEX KEY: 0001789507 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35420 FILM NUMBER: 221326884 MAIL ADDRESS: STREET 1: C/O ASSERTIO THERAPEUTICS, INC. STREET 2: 100 SOUTH SAUNDERS ROAD, SUITE 300 CITY: LAKE FOREST STATE: IL ZIP: 60045 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ChemoCentryx, Inc. CENTRAL INDEX KEY: 0001340652 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943254365 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 835 INDUSTRIAL ROAD STREET 2: SUITE 600 CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650-210-2900 MAIL ADDRESS: STREET 1: 835 INDUSTRIAL ROAD STREET 2: SUITE 600 CITY: SAN CARLOS STATE: CA ZIP: 94070 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-10-20 1 0001340652 ChemoCentryx, Inc. CCXI 0001789507 Wheadon David E. C/O CHEMOCENTRYX, INC. 835 INDUSTRIAL ROAD, SUITE 600 SAN CARLOS CA 94070 1 0 0 0 Restricted Stock Unit 2022-10-20 4 D 0 22274 D Common Stock 22274 0 D Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the board of directors of the Company became fully vested and was cancelled and converted into the right to receive an amount in cash, (Continued from Footnote 1) less applicable withholding taxes and without interest, equal to (x) the total number of shares of common stock, par value $0.001 per share, of the Company underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date. /s/ Susan M. Kanaya, as Attorney-in-Fact 2022-10-20